Details for Patent: 6,608,075

Title:	Use of methylnaltrexone and related compounds
Abstract:	A method for preventing or treating opioid induced changes in gastrointestinal motility. The method comprises administering methylnaltrexone or another quaternary derivative of noroxymorphone to a patient prior to the administration of an opioid or after the onset of side effects induced by the administration of an opioid, wherein the methylnaltrexone or quaternary derivative is administered orally in an enterically coated form.
Inventor(s):	Foss; Joseph F. (Chicago, IL), Roizen; Michael F. (Chicago, IL), Moss; Jonathan (Chicago, IL), Yuan; Chun-Su (Chicago, IL), Drell; William (San Diego, CA)
Assignee:	The University of Chicago (Chicago, IL) U.R. Labs (Reno, NV)
Filing Date:	May 21, 2001
Application Number:	09/862,169
Claims:	1. A method for preventing opioid induced inhibition of gastrointestinal motility comprising orally administering an enterically coated quaternary derivative of noroxymorphone to a patient prior to the administration of an opioid, wherein the patient's plasma level of the quaternary derivative of noroxymorphone does not exceed 50 ng/ml. 2. The method of claim 1 wherein the quaternary derivative is methylnaltrexone. 3. The method of claim 2 wherein the methylnaltrexone is administered at a dosage 0.1 to 40.0 mg of active drug per kg body weight. 4. The method of claim 3 wherein the methylnaltrexone is administered orally at a dosage of about 0.1 to about 10 mg/kg body weight. 5. The method of claim 2 wherein the methylnaltrexone is administered as an enterically coated tablet or capsule. 6. The method of claim 2 wherein the patient's plasma level of methylnaltrexone remains below 25 ng/ml. 7. The method of claim 2 wherein the enteric coating provides time release of the methylnaltrexone. 8. The method of claim 1 wherein the inhibition of gastrointestinal motility is manifested as constipation. 9. The method of claim 1, wherein the patient has had surgery. 10. A method for treating opioid induced inhibition of gastrointestinal motility comprising orally administering an enterically coated quaternary derivative of noroxymorphone to a patient subsequent to the administration of an opioid, wherein the patient's plasma level of the quaternary derivative of noroxymorphone does not exceed 50 ng/ml. 11. The method of claim 10 wherein the quaternary derivative is methlynaltrexone. 12. The method of claim 11 wherein the patient's plasma level of methylnaltrexone remains below 25 ng/ml. 13. The method of claim 11 wherein the methylnaltrexone is administered at a dosage 0.1 to 40.0 mg of active drug per kg body weight. 14. The method of claim 13 wherein the methylnaltrexone is administered orally at a dosage of about 0.1 to about 10 mg/kg body weight. 15. The method of claim 11 wherein the methylnaltrexone is administered as an enterically coated tablet or capsule. 16. The method of claim 11 wherein the enteric coating provides time release of the methylnaltrexone. 17. The method of claim 10 wherein the inhibition of gastrointestinal motility is manifested as constipation. 18. The method of claim 10 wherein the constipation is induced by endogenous opioids. 19. The method of claim 10, wherein the patient has had surgery. 20. A method for treating endogenous opioid induced inhibition of gastrointestinal motility comprising orally administering an enterically coated quaternary derivative of noroxymorphone to a patient in an amount effective to treat the inhibition, wherein the inhibition is induced by endogenous opioids. 21. The method of claim 20, wherein the quaternary derivative of noroxymorphone is methylnaltrexone. 22. The method of claim 21, wherein the methylnaltrexone is administered in a tablet or capsule. 23. A method for preventing inhibition of gastrointestinal motility in a patient receiving an opioid for pain resulting from surgery comprising administering a quaternary derivative of noroxymorphone to the patient in an amount effective to prevent the inhibition. 24. The method of claim 23, wherein the quaternary derivative of noroxymorphone is methylnaltrexone. 25. The method of claim 24, wherein the methylnaltrexone is administered parenterally. 26. The method of claim 24, wherein the methylnaltrexone is administered at a dosage of about 0.1 to about 40 mg/kg body weight. 27. The method of claim 24, wherein the methylnaltrexone is administered orally. 28. The method of claim 27, wherein the methylnaltrexone is administered as an enterically coated tablet or capsule. 29. The method of claim 24, wherein the patient's plasma level of methylnaltrexone does not exceed 50 ng/ml. 30. A method for treating inhibition of gastrointestinal motility in a patient receiving an opioid for pain resulting from surgery comprising administering a quaternary derivative of noroxymorphone to the patient in an amount effective to treat the inhibition. 31. The method of claim 30, wherein the quaternary derivative of noroxymorphone is methylnaltrexone. 32. The method of claim 31, wherein the methylnaltrexone is administered parenterally. 33. The method of claim 31, wherein the methylnaltrexone is administered subsequent to the opioid. 34. The method of claim 31, wherein the methylnaltrexone is administered at a dosage of about 0.1 to about 40 mg/kg body weight. 35. The method of claim 31, wherein the methylnaltrexone is administered orally. 36. The method of claim 35, wherein the methylnaltrexone is administered as an enterically coated tablet or capsule. 37. The method of claim 31, wherein the patient's plasma level of methylnaltrexone does not exceed 50 ng/ml. 38. The method of claim 31, wherein the quaternary derivative of noroxymorphone is administered subsequent to the opioid.